Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 55Neoplasm Metastasis 5Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Neoplasms 1Malignant Neoplasms of Female Genital Organs 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1HR-positive, HER2-negative Breast Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genital Neoplasms, Female 1Genetic Diseases, Inborn 1Estrogen Receptor Positive Breast Cancer 1ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer 1Disease Progression 1

Interventions

palbociclib 2Letrozole 2venetoclax 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasm Female × Fulvestrant × Clear all
NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Borstkanker Onderzoek Groep

Phase 3 Active not recruiting
1,050 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡